Danish firm Genmab (CPH: GMAB) was trading nearly 4% lower on Friday afternoon after the company lost out in a dispute with the Johnson & Johnson (NYSE: JNJ) subsidiary Janssen.
Genmab announced that there had been an award in the binding arbitration of two matters arising under its license agreement with Janssen relating to daratumumab, a multiple myeloma drug branded as Darzalex that had global sales exceeding $6 billion last year.
The arbitral tribunal issued an award on Thursday, deciding both issues in favor of Janssen, although Genmab has the time-limited right to appeal and is currently considering its options.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze